Medtronic Sees Unusually High Options Volume (NYSE:MDT)

Medtronic PLC (NYSE:MDT) saw unusually large options trading on Thursday. Traders purchased 24,238 put options on the stock. This represents an increase of 45% compared to the average volume of 16,739 put options.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced FDA clearance and CE Mark milestones for its Affera Prism-2 Mapping Software, along with CE Mark approval for the PulseSelect ProxBox Adapter. The approvals expand the company’s cardiac ablation and mapping capabilities and could support adoption of its electrophysiology portfolio. Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
• Positive Sentiment: The FDA cleared Medtronic’s LigaSure RAS Maryland jaw for use with its Hugo robotic-assisted surgery system in the United States. The device broadens Hugo’s instrument lineup and may make the platform more attractive to hospitals evaluating robotic surgery systems. Medtronic receives FDA clearance for LigaSure RAS device
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating and assigned a $110 price target, implying substantial upside from recent trading levels. The endorsement supports the view that Medtronic’s valuation and product pipeline remain attractive. TD Cowen rating update
• Neutral Sentiment: Commentary from Motley Fool and Zacks describes Medtronic as a potentially attractive long-term value stock, citing its valuation, financial profile and strategy. These opinions may support investor interest but do not represent new company-specific catalysts.
• Neutral Sentiment: Medtronic’s William J. Peine was named the 2026 Inventor of the Year for patented innovations related to the Hugo robotic-assisted surgery system. The recognition highlights research strength but has limited immediate earnings impact. IPO Education Foundation names Medtronic inventor of the year
• Negative Sentiment: Put-option volume rose about 45% above its average, indicating increased bearish speculation or downside hedging. This options activity may be contributing to short-term weakness, although it does not by itself confirm a fundamental deterioration.

Insider Activity

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Medtronic

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ipsen Advisor Group LLC boosted its position in Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after purchasing an additional 101 shares during the period. Arlington Trust Co LLC increased its position in Medtronic by 11.6% in the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after buying an additional 120 shares during the period. Bigelow Investment Advisors LLC lifted its stake in Medtronic by 1.1% in the first quarter. Bigelow Investment Advisors LLC now owns 11,125 shares of the medical technology company’s stock valued at $964,000 after buying an additional 121 shares during the last quarter. Bank & Trust Co lifted its stake in Medtronic by 2.8% in the second quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock valued at $342,000 after buying an additional 121 shares during the last quarter. Finally, Integrity Alliance LLC. boosted its holdings in shares of Medtronic by 1.7% during the second quarter. Integrity Alliance LLC. now owns 7,388 shares of the medical technology company’s stock valued at $578,000 after acquiring an additional 125 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Performance

MDT traded down $0.32 during trading hours on Thursday, hitting $85.97. 12,790,407 shares of the stock were exchanged, compared to its average volume of 9,199,728. The stock has a market cap of $109.96 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 1.98 and a beta of 0.56. The stock has a 50-day simple moving average of $90.00 and a 200-day simple moving average of $84.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts anticipate that Medtronic will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s dividend payout ratio is currently 70.94%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Stifel Nicolaus boosted their target price on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research report on Wednesday, September 2nd. Sanford C. Bernstein cut their target price on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Evercore set a $105.00 price target on shares of Medtronic in a research report on Monday, July 6th. Finally, Truist Financial reiterated a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a research note on Wednesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $103.92.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.